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Introduction {#sec001}
============

Brucellosis is a systemic infection caused by facultative intracellular bacteria of the genus *Brucella* and manifests as fever of unknown origin. It remains a critical public health issue in the Mediterranean region and other developing countries \[[@pone.0191993.ref001]\]. Moreover, brucellosis is an occupational disease in developed countries, and is contacted by ingestion of contaminated foods imported from other parts of the world \[[@pone.0191993.ref002]--[@pone.0191993.ref004]\]. For many years, the most commonly used antibiotics for treatment of brucellosis were tetracycline, trimethoprim-sulfamethoxazole, aminoglycosides, rifampicin, quinolones, chloramphenicol, doxycycline, and streptomycin \[[@pone.0191993.ref005]--[@pone.0191993.ref007]\]. Currently, the standard treatment regimens for brucellosis include a combination of the above antibiotics owing to its higher incidence of failure or relapse in patients who received monotherapy \[[@pone.0191993.ref007]\].

According to the findings of Food and Agriculture Organization-WHO Expert Committee on Brucellosis in 1986, combination of oral rifampin (600--900 mg/day) and doxycycline (200 mg/day) for 6 weeks was the treatment of choice in patients with acute brucellosis \[[@pone.0191993.ref008]\]. Doxycycline has already been widely used in the treatment of brucellosis owing to its longer half-life and fewer side effects. But doxycycline combined with streptomycin might induce a higher cure rate and lower relapse rate.

Several trials have indicated that rifampicin therapy may increase the risk of overall failure \[[@pone.0191993.ref009]--[@pone.0191993.ref012]\], whereas the results of 10 other randomized controlled trials (RCTs) showed no significant difference between rifampicin and streptomycin for overall failure \[[@pone.0191993.ref013]--[@pone.0191993.ref022]\]. Clarification regarding the optimal treatment strategies in patients with brucellosis is particularly important, as this has not been definitively determined. Therefore, we attempted a large-scale examination of the available RCTs to determine the comparison of rifampicin and streptomycin in patients with brucellosis. Furthermore, we explored if the treatment effects differed in patients with different characteristics.

Methods {#sec002}
=======

Data sources, search strategy, and selection criteria {#sec003}
-----------------------------------------------------

This review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement issued in 2009 ([S1 Checklist](#pone.0191993.s001){ref-type="supplementary-material"}) \[[@pone.0191993.ref023]\].

Studies with a randomized controlled design that evaluated the effect of rifampicin compared with streptomycin in patients with brucellosis were eligible for inclusion in this meta-analysis, with no restrictions on language or publication status. Three electronic databases (PubMed, EmBase, and Cochrane Library) were searched for published studies from database inception through December 2016. The search terms used were (\"brucella\" OR \"brucellosis\" OR \"human brucellosis\") AND (\"treatment\" OR \"therapy\") AND \"clinical trial.\" The details of search terms for each database are listed in [S1 Table](#pone.0191993.s004){ref-type="supplementary-material"}. Similar terms were used to search [http://www.ClinicalTrials.gov](http://www.clinicaltrials.gov) for ongoing RCTs, which had been registered as completed but were not yet published. Finally, manual searches of reference lists from all the relevant studies were conducted to identify any potential eligible studies. The study topic, design, disease status, intervention, control, and outcomes reported were used to identify the potential included studies.

A study was eligible for inclusion if the following criteria were met: randomized controlled design; patients with human brucellosis; patients received rifampicin or streptomycin; and the study that reported the incidence of overall failure or relapse. The exclusion criteria included were as follows: repeated literature; literature that contained unrelated or missing information; study of brucellosis in animals; literature that did not report any desirable outcomes; or study on human tissues.

Data collection and quality assessment {#sec004}
--------------------------------------

Data collection and quality assessment were independently performed by two reviewers. Any inconsistencies were adjudicated by an additional reviewer with reference to the original studies. The collected data included first author's name, publication year, country, sample size, mean age, percentage of male participants, intervention, and control. The outcome variables included overall failure and relapse. One author entered the retrieved information into the computer, while the other author checked it. The Cochrane Collaboration's tool was employed to evaluate the methodological quality due to its fairly comprehensive nature and has partially validated the quality evaluation of RCTs in meta-analysis \[[@pone.0191993.ref024]\]. It is based on the following six subscales: sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias. The summary risk for bias was defined as low, high, or unclear.

Statistical analysis {#sec005}
--------------------

The effect of rifampicin on the risk of overall failure and relapse compared with streptomycin was evaluated based on the occurred events and total patients in each group in an individual study. The random-effects model was employed to calculate the relative risks (RRs) and 95% confidence intervals (CIs) for rifampicin versus streptomycin for the treatment of human brucellosis \[[@pone.0191993.ref025],[@pone.0191993.ref026]\]. The heterogeneity among trials was investigated by using the Q statistic and p\<0.10 was regarded as an indication of significant heterogeneity \[[@pone.0191993.ref027],[@pone.0191993.ref028]\]. Sensitivity analysis was conducted to illustrate the influence of a single study on the meta-analysis \[[@pone.0191993.ref029]\]. Subgroup analyses were conducted for overall failure and relapse on the basis of publication year, country, sample size, mean age, and percentage male. P values for heterogeneity between subgroups were evaluated by Chi-square test \[[@pone.0191993.ref030]\]. Funnel plots, Egger \[[@pone.0191993.ref031]\] and Begg \[[@pone.0191993.ref032]\] tests, were employed to evaluate the publication bias for overall failure and relapse. P values for the summary results are 2-sided and p\<0.05 was considered statistically significant. All statistical analyses were performed using STATA software (version 12.0; Stata Corporation, College Station, TX, USA) and the study quality assessment using Review Manager, version 5.3 (Cochrane Collaboration, Oxford, England).

Results {#sec006}
=======

The primary search retrieved 527 articles. After scanning the titles and abstracts, 502 irrelevant or duplicate articles were excluded. Of the total, 25 potentially eligible studies were retrieved, and 14 RCTs met the inclusion criteria of this meta-analysis \[[@pone.0191993.ref009]--[@pone.0191993.ref022]\]. Results of the study-selection process are shown in [Fig 1](#pone.0191993.g001){ref-type="fig"}. The search of [http://www.ClinicalTrials.gov](http://www.clinicaltrials.gov) and the reference lists of potentially relevant studies yielded no studies that met the inclusion criteria. [Table 1](#pone.0191993.t001){ref-type="table"} summarized the general characteristics of the included studies. The sample size ranged from 19 to 194, with a total of 1,383 patients with human brucellosis. Eleven trials were conducted in Europe and the remaining three trials in Asia. The mean or median age ranged from 26.4 to 46.0 years and the percentage of male participants ranged from 37.0 to 82.0%. All patients in the included trials received doxycycline as background therapy. The quality assessment of 14 included trials was conducted using the Cochrane Collaboration tool, and the results of quality analysis are presented in Figs [2](#pone.0191993.g002){ref-type="fig"} and [3](#pone.0191993.g003){ref-type="fig"}.

![Study selection process.](pone.0191993.g001){#pone.0191993.g001}

![Risk of bias graph of included RCTs.](pone.0191993.g002){#pone.0191993.g002}

![Risk of bias summary of included RCTs.](pone.0191993.g003){#pone.0191993.g003}
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###### Baseline characteristics of included patients and quality assessment.

![](pone.0191993.t001){#pone.0191993.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                     Publication years   Country                 Sample size   Mean age (years)   Percentage male (%)   Intervention                                                                                           Control
  ----------------------------------------- ------------------- ----------------------- ------------- ------------------ --------------------- ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------
  Acocella \[[@pone.0191993.ref013]\]       1989                France, Greece, Spain   146           43.0               58.8                  Doxycycline 1× 200 mg for 45 days + rifampicin 1× 900 mg for 45 days                                   Doxycycline 1× 200 mg for 45 days + streptomycin 1×1 g for 21 days

  Ariza \[[@pone.0191993.ref009]\]          1985                Spain                   56            33.0               80.0                  Doxycycline 1×100 mg for 30 days (45 days)+rifampicin 15 mg/kg/day for 30 days (45 days)               Doxycycline 1×100 mg or tetracycline hydrochloride 4×0.5g for 30 days (45 days)+streptomycin 1×1 g for 21 days

  Ariza \[[@pone.0191993.ref014]\]          1992                Spain                   111           26.4               71.6                  Doxycycline 2×100 mg for 45 days + rifampicin 15 mg/kg/day for 45 days                                 Doxycycline 2×100 mg for 45 days+streptomycin 1×1 g for 15 days

  Bayindir\[[@pone.0191993.ref015]\]        2003                Turkey                  102           40.5               55.0                  Doxycycline 2×100 mg for 45 days + rifampicin 15 mg/kg/day for 45 days                                 Doxycycline 2×100 mg for 45 days+Streptomycin 1×1 g for 15 days

  Colmenero \[[@pone.0191993.ref016]\]      1989                Spain                   111           33.1               69.4                  Doxycycline 2×100 mg for 45 days (60 days)+rifampicin 15 mg/kg/day for 45 days (60 days)               Doxycycline 2×100 mg for 30 days (60 days)+Streptomycin 1×1 g for 21 days

  Colmenero \[[@pone.0191993.ref017]\]      1994                Spain                   19            33.3               65.0                  Doxycycline 2×100 mg for 6 weeks (12 weeks)+rifampicin 10--15 mg/kg/day for 6 weeks (12 weeks)         Doxycycline 2×100mg for 6weeks (12weeks)+Streptomycin 1×1 g for 3 weeks

  Dorado\[[@pone.0191993.ref018]\]          1988                Spain                   73            37.2               37.0                  Doxycycline 1×200 mg for 28 days + rifampicin 1×1200 mg for 7 days, followed by 1×600 mg for 21 days   Doxycycline 1×200 mg for 40 days+Streptomycin 1×1 g for 21 days

  Ersoy\[[@pone.0191993.ref019]\]           2005                Turkey                  129           36.4               52.6                  Doxycycline 200 mg/day for 6 weeks + rifampicin 600 mg/day for 6 weeks                                 Doxycycline 100 mg/day for 6 weeks+\
                                                                                                                                                                                                                                                      Streptomycin 1 g/day for 3 weeks

  Kosmidis\[[@pone.0191993.ref020]\]        1982                Greece                  29            NA                 NA                    Doxycycline 1×200 mg for 45 days+rifampicin 1×900 mg for 45 days                                       Doxycycline 1×200 mg for 45 days+Streptomycin 1×1 g for 21 days

  Montejo\[[@pone.0191993.ref021]\]         1993                Spain                   130           46.0               74.0                  Doxycycline 1×200 mg for 6 weeks + rifampicin 1×900 mg for 6 weeks                                     Doxycycline 1×200 mg for 6 weeks +Streptomycin 1×1 g for 2 or 3 weeks

  Rodriguez Zap\[[@pone.0191993.ref022]\]   1987                Spain                   72            36.0               80.0                  Doxycycline 1×200 mg for 45 days + rifampicin 1×900 mg for 45 days                                     Doxycycline 2×200 mg for 21 days+Streptomycin 1×1 g for 21 days

  Solera \[[@pone.0191993.ref010]\]         1991                Spain                   84            32.0               77.0                  Doxycycline 2×100 mg for 45 days + rifampicin 1×900 mg for 21 days                                     Doxycycline 2×100 mg for 45 days+Streptomycin 1×1 g for 14 days

  Solera \[[@pone.0191993.ref011]\]         1995                Spain                   194           33.5               82.0                  Doxycycline 2×100 mg for 45 days + rifampicin 1×900 mg for 45 days                                     Doxycycline 2×100 mg for 45 days+Streptomycin 1×1 g for 14 days

  Hashemi \[[@pone.0191993.ref012]\]        2012                Iran                    127           39.3               55.1                  Doxycycline 1×200 mg for 6 weeks + rifampicin 15 mg/kg/day for 6 weeks                                 Doxycycline 1×200 mg for 6 weeks + Streptomycin 1×1 g for 3 weeks
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

After pooling all the included trials, the summary RR indicated that rifampicin therapy significantly increased the incidence of overall failure compared with streptomycin (RR: 2.36; 95% CI: 1.72--3.23; P\<0.001; [Fig 4](#pone.0191993.g004){ref-type="fig"}). The heterogeneity test revealed no evidence of heterogeneity (I^2^ = 0.0%, P = 0.820). Sensitivity analysis concluded that the data was not affected by sequential exclusion of individual trials ([S1 Fig](#pone.0191993.s002){ref-type="supplementary-material"}).

![Effect of rifampicin therapy on the incidence of overall failure.](pone.0191993.g004){#pone.0191993.g004}

Data for the effect of rifampicin on the risk of relapse were available in 13 trials. We noted that rifampicin therapy was associated with higher risk of relapse compared with streptomycin (RR: 2.74; 95% CI: 1.80--4.19; P\<0.001; [Fig 5](#pone.0191993.g005){ref-type="fig"}), and no evidence of heterogeneity was observed (I^2^ = 0.0%, P = 0.973). Sensitivity analysis was conducted for relapse, and concluded no affect on the data by excluding each specific study ([S2 Fig](#pone.0191993.s003){ref-type="supplementary-material"}).

![Effect of rifampicin therapy on the incidence of relapse.](pone.0191993.g005){#pone.0191993.g005}

Although heterogeneity analysis showed p\>0.10 for overall failure and relapse, subgroup analyses were conducted for overall failure and relapse to evaluate the effect of rifampicin in the treatment of human brucellosis within specific subpopulations ([Table 2](#pone.0191993.t002){ref-type="table"}). Overall, we noted that there was no significant difference between rifampicin and streptomycin for overall failure when the mean age of the patients was \>40 (RR: 1.92; 95% CI: 0.93--3.97; p = 0.078). Additionally, men with brucellosis who received rifampicin had a higher failure risk than women (ratio of RR: 1.62; 95% CI: 0.85--3.07; p = 0.140). Results of subgroup analyses based on other factors were consistent with the overall analysis.

10.1371/journal.pone.0191993.t002

###### Subgroup analysis.

![](pone.0191993.t002){#pone.0191993.t002g}

  Outcomes              Group               RR and 95%CI   P value   Heterogeneity (%)   P value for heterogeneity   Ratios of RR
  --------------------- ------------------- -------------- --------- ------------------- --------------------------- --------------
  Overall failure       Publication year                                                                             
  After 2000            2.12 (1.18--3.82)   0.012          3.9       0.353               0.86 (0.43--1.73)           0.679
  Before 2000           2.46 (1.69--3.59)   \<0.001        0.0       0.807                                           
  Country                                                                                                            
  Europe                2.46 (1.69--3.59)   \<0.001        0.0       0.807               1.16 (0.58--2.33)           0.679
  Asia                  2.12 (1.18--3.82)   0.012          3.9       0.353                                           
  Sample size                                                                                                        
  100 or more           2.39 (1.62--3.51)   \<0.001        0.0       0.870               1.04 (0.53--2.02)           0.961
  \<100                 2.30 (1.34--3.97)   0.003          0.0       0.438                                           
  Mean age                                                                                                           
  40 or more            1.92 (0.93--3.97)   0.078          0.0       0.742               0.74 (0.33--1.67)           0.473
  \<40                  2.58 (1.81--3.67)   \<0.001        0.0       0.802                                           
  Percentage male (%)                                                                                                
  70 or more            3.14 (1.97--4.98)   \<0.001        0.0       0.927               1.62 (0.85--3.07)           0.140
  \<70                  1.94 (1.25--3.01)   0.003          0.0       0.821                                           
  Relapse               Publication year                                                                             
  After 2000            2.45 (1.03--5.83)   0.044          0.0       0.432               0.86 (0.32--2.33)           0.770
  Before 2000           2.84 (1.75--4.61)   \<0.001        0.0       0.975                                           
  Country                                                                                                            
  Europe                2.84 (1.75--4.61)   \<0.001        0.0       0.975               1.16 (0.43--3.13)           0.770
  Asia                  2.45 (1.03--5.83)   0.044          0.0       0.432                                           
  Sample size                                                                                                        
  100 or more           2.89 (1.61--5.21)   \<0.001        0.0       0.926               1.12 (0.48--2.60)           0.798
  \<100                 2.59 (1.41--4.76)   0.002          0.0       0.807                                           
  Mean age                                                                                                           
  40 or more            3.15 (1.07--9.31)   0.038          0.0       0.596               1.18 (0.36--3.83)           0.783
  \<40                  2.67 (1.68--4.25)   \<0.001        0.0       0.909                                           
  Percentage male (%)                                                                                                
  70 or more            3.16 (1.79--5.60)   \<0.001        0.0       0.906               1.39 (0.59--3.27)           0.457
  \<70                  2.28 (1.20--4.34)   0.012          0.0       0.797                                           

A review of the funnel plots could not exclude publication bias for overall failure and relapse ([Fig 6](#pone.0191993.g006){ref-type="fig"}). Results of the Egger's and Begg's tests showed no evidence of publication bias for overall failure (p = 0.454 for Egger; p = 0.827 for Begg) and relapse (p = 0.230 for Egger; p = 0.583 for Begg).

![Funnel plots.](pone.0191993.g006){#pone.0191993.g006}

Discussion {#sec007}
==========

The current meta-analysis investigated RCTs that compared rifampicin and streptomycin for the treatment of human brucellosis. This comprehensive quantitative study included 1,383 patients with brucellosis from 14 RCTs with a broad range of characteristics. The findings of this study indicated that the incidence of overall failure and relapse was significantly increased for rifampicin over streptomycin. However, a significant difference was not observed if the mean age of the patients was greater than 40 years.

A previous meta-analysis suggested that doxycycline-rifampicin was associated with higher risk of overall failure and relapse when compared with doxycycline-streptomycin for patients with bacteremia or complicated brucellosis. Further, the triple regimen of doxycycline, rifampicin, and aminoglycoside was superior to doxycycline-streptomycin in the treatment of brucellosis. These findings reported no differences between gentamicin and streptomycin and doxycycline plus rifampicin or streptomycin was superior to quinolones plus rifampicin. Finally, they indicated that triple or dual drug regimens were associated with a lower risk of failure than monotherapy when administered for a similar duration \[[@pone.0191993.ref033]\]. Although this study provided comprehensive comparisons of different treatment regimens, the effect of doxycycline that was available in one of the trial arms and the pooled analyses according to the patients' characteristics were not calculated. Our meta-analysis also found that the combination of doxycycline with streptomycin was superior to doxycycline plus rifampicin. In addition, there was no significant difference between quinolones plus rifampicin and doxycycline plus rifampicin. These results indicated that intramuscular injection, access to care, and cost should be considered to make a decision when prescribing these regimens \[[@pone.0191993.ref034]\]. However, no evaluation was conducted on how the treatment effects differed in patients with different characteristics. Solís García del Pozo suggested favorable outcomes of doxycycline-streptomycin over doxycycline-rifampicin, while no significant differences between doxycycline-streptomycin and doxycycline-gentamicin were observed \[[@pone.0191993.ref035]\]. Although similar conclusions were found in our meta-analysis, the treatment in our study or patients with specific characteristics was conducted, and the comparisons of treatment effects between the subgroups were calculated. Furthermore, the current study included several additional studies and provided more stable outcomes with high statistical power.

Although significant differences were observed, the methodological evaluation of individual trials was limited, as only five trials provided clear information on randomization, blinding, withdrawals and dropouts, and used intention-to-treat analysis. Most of the included trials were of low study quality, which might contribute to the unreliability of the results. Consequently, considering the unsatisfactory quality of majority of the included trials, the findings of this study should be cautiously recommended for the treatment of patients with brucellosis.

The pooled data showed a significantly increased risk of overall failure and relapse in patients who received rifampicin plus doxycycline compared with streptomycin plus doxycycline. Several included trials reported consistent conclusions. Ariza et al. conducted a trial based on 56 patients with human brucellosis to compare the efficacy of rifampicin-doxycycline with streptomycin-doxycycline. Results revealed that rifampicin-doxycycline was less effective in the prevention of relapse than streptomycin-doxycycline when both were administered for 30 days. After which, they recommended a longer period of treatment of rifampicin-doxycycline to yield a lower relapse rate \[[@pone.0191993.ref009]\]. Furthermore, Solera et al. suggested doxycycline-rifampicin therapy was less effective than doxycycline-streptomycin in patients with acute brucellosis in terms of therapeutic efficacy and relapse \[[@pone.0191993.ref010],[@pone.0191993.ref011]\]. In addition, Hashemi et al. recommended doxycycline-streptomycin as a first-line therapeutic regimen and combined doxycycline-streptomycin and ofloxacin-rifampicin as the second-line treatment regimen for the treatment of brucellosis \[[@pone.0191993.ref012]\]. However, in most other trials, no significant differences were detected for overall failure and relapse. A possible explanation for this could be lower than expected event rate and smaller sample size, which led to broad confidence intervals, i.e., no statistically significant differences.

Subgroup analysis suggested no significant difference between these two regimens if the patient's mean age was \>40 years, which might be due to that the effect of treatment in older patients was diminished compared with younger patients. Although no statistically significant differences between the subgroups were observed, several trends were identified and should be considered and verified in a further large-scale RCT. These conclusions may vary as smaller trials were included in each subset and should be verified further in future studies. We therefore provided a relative result and a comprehensive review.

Several limitations of this meta-analysis were acknowledged. (1) The study comprised mostly trials with a low study quality and the results might vary. (2) Data were taken from only published studies and publication bias may be inevitable. (3) Summary analysis used pooled data as individual data were not available, which restricted a more detailed analysis.

In conclusion, rifampicin was associated with higher incidence of overall failure and relapse when compared with streptomycin in patients with brucellosis. Furthermore, age and gender might influence the treatment effect. We strongly recommend that the interaction of these two factors should be clarified and explore more effective treatment regimens in future studies.
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